文献速递瓣膜病与结构性心脏病

经股静脉三尖瓣置换术一年结局:TRISCEND研究

Transfemoral tricuspid valve replacement and one-year outcomes: the TRISCEND study.
PubMed 文献 · Eur Heart J · 2023-01-01

TRISCEND前瞻性单臂多中心研究纳入176例有症状的重度及以上三尖瓣反流患者,评估经导管三尖瓣置换术的安全性和性能。一年随访显示三尖瓣反流显著减少,每搏输出量和心输出量增加,临床、功能和生活质量指标持续改善。

要点

  • 经股静脉EVOQUE三尖瓣置换术后一年三尖瓣反流降至轻度及以下达97.6%。
  • 每搏输出量增加10.5±16.8 mL,心输出量增加0.6±1.2 L/min。
  • 全因死亡率9.1%,心力衰竭住院率10.2%,生活质量和功能状态显著改善。

核心结论

  • 在老年、合并症多的中度及以上三尖瓣反流患者中,经股静脉EVOQUE三尖瓣置换术可持续减少三尖瓣反流,显著增加每搏输出量和心输出量,并保持高生存率和低住院率,临床、功能和生活质量结局改善持续至一年。

研究设计与样本

  • 前瞻性、单臂、多中心TRISCEND研究纳入176例有症状的中度及以上三尖瓣反流患者,评估经导管三尖瓣置换术的安全性和性能。

主要发现

  • 三尖瓣反流降至轻度及以下者占97.6%(P < .001)。
  • 每搏输出量增加10.5 ± 16.8 mL(P < .001),心输出量增加0.6 ± 1.2 L/min(P < .001)。
  • 纽约心脏协会心功能I或II级达93.3%(P < .001),堪萨斯城心肌病问卷评分增加25.7分(P < .001),六分钟步行距离增加56.2 m(P < .001)。
  • 全因死亡率为9.1%,因心力衰竭住院者占10.2%。

临床怎么用

  • 对于有症状的中度及以上三尖瓣反流患者,经股静脉EVOQUE三尖瓣置换术可作为一种改善血流动力学和生活质量的介入选择。

局限性

  • 研究为单臂设计,无对照组,无法直接比较与其他治疗策略的差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: For patients with symptomatic, severe tricuspid regurgitation (TR), early results of transcatheter tricuspid valve (TV) intervention studies have shown significant improvements in functional status and quality of life associated with right-heart reverse remodelling. Longer-term follow-up is needed to confirm sustained improvements in these outcomes. METHODS: The prospective, single-arm, multicentre TRISCEND study enrolled 176 patients to evaluate the safety and performance of transcatheter TV replacement in patients with ≥moderate, symptomatic TR despite medical therapy. Major adverse events, reduction in TR grade and haemodynamic outcomes by echocardiography, and clinical, functional, and quality-of-life parameters are reported to one year. RESULTS: Enrolled patients were 71.0% female, mean age 78.7 years, 88.0% ≥ severe TR, and 75.4% New York Heart Association classes III-IV. Tricuspid regurgitation was reduced to ≤mild in 97.6% (P < .001), with increases in stroke volume (10.5 ± 16.8 mL, P < .001) and cardiac output (0.6 ± 1.2 L/min, P < .001). New York Heart Association class I or II was achieved in 93.3% (P < .001), Kansas City Cardiomyopathy Questionnaire score increased by 25.7 points (P < .001), and six-minute walk distance increased by 56.2 m (P < .001). All-cause mortality was 9.1%, and 10.2% of patients were hospitalized for heart failure. CONCLUSIONS: In an elderly, highly comorbid population with ≥moderate TR, patients receiving transfemoral EVOQUE transcatheter TV replacement had sustained TR reduction, significant increases in stroke volume and cardiac output, and high survival and low hospitalization rates with improved clinical, functional, and quality-of-life outcomes to one year. Funded by Edwards Lifesciences, TRISCEND ClinicalTrials.gov number, NCT04221490.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Kodali S, Hahn RT, Makkar R, et al. Transfemoral tricuspid valve replacement and one-year outcomes: the TRISCEND study. Eur Heart J. 2023. PMID: 37930776. doi:10.1093/eurheartj/ehad667

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。